MaxCyte Grants Inducement Awards to New Senior Vice President

ROCKVILLE, Md., Sept. 11, 2026 /CourierPR/ -- MaxCyte, Inc., a leading cell-engineering company, has announced the granting of inducement awards to Sidharth Kapileshwar, who has recently joined the firm as Senior Vice President and Chief Corporate Development Officer. The awards, granted under the company’s 2026 Inducement Plan, consist of stock options and a restricted stock unit (RSU) award.

Kapileshwar was granted 220,000 stock options, which will vest over a four-year period. The options are scheduled to vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next 36 months, contingent upon his continuous employment with MaxCyte. The stock options have a ten-year term and an exercise price of $1.29, the closing price of MaxCyte’s common stock on the grant date.

Additionally, Kapileshwar received an RSU award for 110,000 shares of MaxCyte’s common stock. These RSUs are also subject to a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the remaining shares vesting in three equal annual installments thereafter, provided he remains employed with the company.

The inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4), which requires such grants to be material to the employee’s entry into employment. The move is aimed at retaining and incentivizing key talent as MaxCyte continues to expand its operations and advance the development of next-generation cell therapies.

MaxCyte’s commitment to driving the discovery, development, and commercialization of cell therapies is evident in its provision of Flow Electroporation® technology and SeQure™ gene editing risk assessment services. These tools enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting the development of safe and effective treatments for human health.

The inducement awards reflect MaxCyte’s strategic focus on attracting and retaining top talent to support its growth and innovation efforts. With Kapileshwar’s expertise in corporate development, the company is poised to strengthen its position in the rapidly evolving field of cell engineering.